This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Piramal Pharma Limited Receives Assessment Orders from the Office of the Navi Mumbai Municipal Corporation, Cess Department CI
Piramal Pharma Limited Receives Order from the Regional Provident Fund Commissioner, Thane South, Levying Damages of INR 1,120,932 Under Bombay Provincial Municipal Corporation (Cess on Entry of Goods) Rules, 1996 CI
Piramal Pharma Gets US FDA's Establishment Inspection Report for Riverview, US Facility MT
Piramal Pharma Forays into Men Grooming Products MT
Piramal Pharma Limited Announces the Launch of BOHEM Product Range CI
Transcript : Piramal Pharma Limited, Q3 2024 Earnings Call, Jan 31, 2024
Piramal Pharma Turns to Profit in Fiscal Q3 MT
Piramal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Piramal Pharma Solutions Commences Opening of Its Antibody-Drug Conjugate Manufacturing Expansion in Grangemouth, Scotland CI
FOCUS -Indian drug manufacturers benefit from Big Pharma interest beyond China RE
Piramal Pharma Gets US FDA's EIR Report After Bethlehem, USA Unit Inspection MT
Jefferies Adjusts Piramal Pharma's Price Target to INR135 From INR125, Keeps at Buy MT
Piramal Pharma Swings to Profit in Fiscal Q2 MT
Transcript : Piramal Pharma Limited, Q2 2024 Earnings Call, Oct 30, 2023
Piramal Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Piramal Pharma Solutions Launches In-Vitro Biology Capabilities At Ahmedabad Discovery Services Site CI
Piramal Pharma Gets Two Observations from US FDA After Inspection of US Facility MT
Piramal Pharma Gets Regulatory Nod to Liquidate Japanese Arm MT
Jefferies Adjusts Piramal Pharma’s Price Target to INR125 From INR115, Keeps at Buy MT
Transcript : Piramal Pharma Limited, Q1 2024 Earnings Call, Aug 04, 2023
Piramal Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Piramal Pharma Gets SEBI Nod for INR10.50 Billion Rights Issue MT
Canada's CDPQ Sells Stake in Piramal Pharma MT
Piramal Critical Care Names President-COO MT
Piramal Pharma Limited's Announces the Appointment of Jeffrey Hampton as President & Chief Operating Officer CI
Chart Piramal Pharma Limited
More charts
Piramal Pharma Limited is an India-based pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. The Company has approximately 17 global facilities and a global distribution network in over 100 countries. The Company's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC's complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain, anesthetics, injectable anti-infectives, and other therapies.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
156 INR
Average target price
168.4 INR
Spread / Average Target
+7.95%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. PPLPHARMA Stock
  4. News Piramal Pharma Limited
  5. Piramal Pharma Gets Regulatory Nod to Liquidate Japanese Arm
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW